Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Biliary Obstruction Workup

  • Author: Jennifer Lynn Bonheur, MD; Chief Editor: Julian Katz, MD  more...
 
Updated: Mar 11, 2015
 

Laboratory Studies

See the list below:

  • Serum bilirubin: Regardless of the cause of cholestasis, serum bilirubin values (especially direct) are usually elevated. However, the degree of hyperbilirubinemia cannot help reliably distinguish between the causes of obstruction.
    • Extrahepatic obstruction: This is typically associated with considerable direct and indirect bilirubin elevation. However, in the early phases of obstruction and with incomplete or intermittent obstruction, serum bilirubin levels may only be mildly elevated. Initially, an increase in the conjugated bilirubin level occurs without affecting the unconjugated bilirubin level because obstruction of the CBD prevents excretion of already conjugated bilirubin into the duodenum. Conjugated bilirubin that does reach the intestine is deconjugated by intestinal bacteria. Unconjugated bilirubin, in contrast to the conjugated form, easily crosses the intestinal epithelial barrier into the blood. It accumulates in the blood because the uptake mechanism and the hepatic cells are overburdened by bilirubin that has already been conjugated but cannot be excreted. Therefore, indirect bilirubin levels rise even in persons with obstructive jaundice.
    • Intrahepatic obstruction: Both conjugated and unconjugated bilirubin fractions may increase in varying proportions. The unconjugated fraction may be increased because of the inability of the damaged cells to conjugate normal amounts of unconjugated serum bilirubin. The increase of the conjugated fraction usually results from metabolic deficiency in the excretory mechanism caused by the inflammatory process of the disease.
  • Alkaline phosphatase (ALP): A membrane-bound enzyme localized to the bile canalicular pole of hepatocytes, ALP is markedly elevated in persons with biliary obstruction. However, high levels of this enzyme are not specific to cholestasis. To determine whether the enzyme is likely to be of hepatic origin, measure gamma-glutamyl transpeptidase (GGT) or 5-prime-nucleotidase. These values tend to parallel the ALP levels in patients with liver disease. GGT is used most commonly. While it is part of the routine evaluation of biliary obstruction, the degree of elevation of ALP cannot be used to reliably discriminate between extrahepatic and intrahepatic causes of biliary obstruction.
    • Extrahepatic obstruction: ALP levels are elevated in nearly 100% of patients, except in some cases of incomplete or intermittent obstruction. Values are usually greater than 3 times the upper limit of the reference range, and in most typical cases, they exceed 5 times the upper limit. An elevation less than 3 times the upper limit is evidence against complete extrahepatic obstruction.
    • Intrahepatic obstruction: ALP levels are usually elevated, and they often are less than 3 times the upper limit of the normal reference range. However, 5-10% of patients have a greater degree of elevation.
  • Serum transaminases: Levels of these are usually only moderately elevated in patients with cholestasis but occasionally may be markedly increased, especially if cholangitis is present.
    • Extrahepatic obstruction: Usually, serum aspartate aminotransferase (AST) levels are not elevated unless secondary acute parenchymal damage is present. When elevations occur, they are usually only mild to moderate (< 10 times the upper reference limit). However, when extrahepatic obstruction occurs acutely, AST values may quickly rise to more than 10 times the normal value, and then they fall after approximately 72 hours. With time and progressive hepatocyte damage caused by distended biliary ductules, an elevation in AST levels may be observed. A 3-fold or more increase in ALT strongly suggests pancreatitis.
    • Intrahepatic obstruction: Alanine aminotransferase (ALT) is predominantly found in the liver, and most elevations are due to intrahepatic disease. Although less specific to the liver, the AST level is also elevated in cases of intrahepatic cholestasis. ALT and AST levels are usually elevated to the same degree in patients with viral hepatitis and those with drug-induced liver damage. In association with alcoholic liver disease, cirrhosis, and metastatic lesions to the liver, the AST level is elevated more frequently than the ALT level. In general, AST levels are usually higher than ALT levels.
  • GGT: These levels are elevated in patients with diseases of the liver, biliary tract, and pancreas when the biliary tract is obstructed. Levels parallel the levels of ALP and 5-prime-nucleotidase in conditions associated with cholestasis. The extreme sensitivity of GGT, as opposed to ALP, limits its usefulness; however, the level helps distinguish hepatobiliary disease as the cause of an isolated rise in ALP.
  • Prothrombin time (PT): This may be prolonged because of malabsorption of vitamin K. Correction of the PT by parenteral administration of vitamin K may help distinguish hepatocellular failure from cholestasis. Little or no improvement occurs in patients with parenchymal liver disease.
  • Hepatitis serology: Because differentiating viral hepatitis from extrahepatic obstructive causes may be difficult, include serologic assays for acute viral hepatitis in the investigation of all patients with cholestasis.
  • Antimitochondrial antibody: The presence of antimitochondrial antibodies, usually in high titers, is indicative of PBC. They are usually absent in patients with mechanical biliary obstruction or PSC.
  • Urine bilirubin: Urine bilirubin normally is absent. When it is present, only conjugated bilirubin is passed into the urine. This may be evidenced by dark-colored urine seen in patients with obstructive jaundice or jaundice due to hepatocellular injury. However, reagent strips are very sensitive to bilirubin, detecting as little as 0.05 mg/dL. Thus, urine bilirubin may be found even in the absence of hyperbilirubinemia or clinical jaundice.
Next

Imaging Studies

See the list below:

  • Plain radiographs are of limited utility to help detect abnormalities in the biliary system. Frequently, calculi are not visualized because few are radiopaque.
  • Ultrasonography (US) is the least expensive, safest, and most sensitive technique for visualizing the biliary system, particularly the gallbladder. Current accuracy is close to 95%.
    • US is the procedure of choice for the initial evaluation of cholestasis and for helping differentiate extrahepatic from intrahepatic causes of jaundice. Extrahepatic obstruction is suggested by the presence of dilated bile ducts, but the presence of normal bile ducts does not exclude obstruction that may be new or intermittent.
    • Visualization of the pancreas, kidney, and blood vessels is also possible.
    • US is considered somewhat limited in its overall ability to help detect the specific cause and level of obstruction. US is not as useful for CBD stones (bowel gas may obscure visualization of the CBD). The cystic duct is also poorly imaged. In addition, it is less useful diagnostically in individuals who are obese.
  • Traditional computed tomography (CT) scan is usually considered more accurate than US for helping determine the specific cause and level of obstruction. In addition, it helps visualize liver structures more consistently than US. The addition of intravenous contrast helps differentiate and define vascular structures and the biliary tract.
    • CT scan has limited value in helping diagnose CBD stones because many of them are radiolucent and CT scan can only image calcified stones. It is also less useful in the diagnosis of cholangitis because the findings that specifically suggest bile duct infection (increased attenuation due to pus, bile duct wall thickening, and gas) are seen infrequently.
    • Lastly, CT scan is expensive and involves exposure to radiation, both of which lessen the routine use CT scans compared to US examinations.
  • Spiral (helical) CT scan improves biliary tract imaging by providing several overlapping images in a shorter time than traditional CT scan and by improving resolution by reducing the presence of respiratory artifacts.
    • CT cholangiography by the helical CT technique is used most often to image the biliary system and makes possible visualization of radiolucent stones and other biliary pathology.[6]
    • Limitations of helical CT cholangiography include reactions to the contrast, which are becoming less frequent. Also, as serum bilirubin levels increase, the ability to visualize the biliary tree diminishes and the ability to fully delineate tumors decreases. Patients are required to hold their breath while images are acquired.
  • Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive way to visualize the hepatobiliary tree. It takes advantage of the fact that fluid (eg, that found in the biliary tree) is hyperintense on T2-weighted images. The surrounding structures do not enhance and can be suppressed during image analysis. However, in its early stages, it was limited in its ability to detect nondilated bile ducts. The advent of rapid acquisition with relaxation enhancement (RARE) sequences and half-Fourier RARE (also known as half-Fourier acquisition single-shot turbo spin-echo or HASTE) sequences can reduce imaging time to a few seconds. This can facilitate imaging in different patient positions to distinguish air from a stone.
    • As with helical CT scan, MRCP gives radiologists the ability to analyze source images and 2- and 3-dimensional projections. Although some techniques require patients to hold their breath for the highest quality images, the time required to complete the scan is decreasing as imaging techniques improve, and alternative procedures capture images between patient breaths.
    • MRCP provides a sensitive noninvasive method of detecting biliary and pancreatic duct stones, strictures, or dilatations within the biliary system. It is also sensitive for helping detect cancer. MRCP combined with conventional MR imaging of the abdomen can also provide information about the surrounding structures (eg, pseudocysts, masses).
    • While ERCP and MRCP may be similarly effective in detecting malignant hilar and perihilar obstruction, MRCP has been shown to be better able to determine the extent and type of tumor as compared to ERCP. In addition, unlike ERCP, MRCP does not require contrast material to be injected to visualize the ductal system, thereby avoiding the morbidity associated with injected contrast.
    • The limitations of MRCP include the contraindications to magnetic resonance imaging. Absolute contraindications include the presence of a cardiac pacemaker, cerebral aneurysm clips, ocular or cochlear implants, and ocular foreign bodies. Relative contraindications include the presence of cardiac prosthetic valves, neurostimulators, metal prostheses, and penile implants.
    • Fluid stasis in the adjacent duodenum or in ascitic fluid may produce image artifacts on MRCP, making it difficult to clearly visualize the biliary tree.
    • The risk of MRCP during pregnancy is not known.
    • Although MRCP currently does not have the capability for the therapeutic applications of the more invasive ERCP, it can be useful for diagnostic purposes and poses less risk to the patient as compared to ERCP.
Previous
Next

Procedures

See the list below:

  • ERCP is an outpatient procedure that combines endoscopic and radiologic modalities to visualize both the biliary and pancreatic duct systems. Endoscopically, the ampulla of Vater is identified and cannulated. A contrast agent is injected into these ducts, and x-ray images are taken to evaluate their caliber, length, and course.
    • It is especially useful for lesions distal to the bifurcation of the hepatic ducts. Besides being a diagnostic modality, ERCP has a therapeutic application because obstructions can potentially be relieved by the removal of stones, sphincterotomy, and the placement of stents and drains. The addition of cholangioscopy to the ERCP, by advancing a smaller "baby" scope through the endoscope into the common duct, allows for biopsies and brushings within the ducts and better identification of lesions seen on cholangiogram.
    • ERCP has a limited capacity to image the biliary tree proximal to the site of obstruction. Also, it cannot be performed if altered anatomy prevents endoscopic access to the ampulla (eg, Roux loop).
    • Complications of this technique include pancreatitis, perforation, biliary peritonitis, sepsis, hemorrhage, and adverse effects from the dye and the drug used to relax the duodenum. The risk of any complication is less than 10%. Severe complications occur in less than 1%.
    • The sensitivity and specificity of ERCP are 89-98% and 89-100%, respectively. ERCP is still considered the criterion standard for imaging the biliary system, particularly if therapeutic intervention is planned.
  • Percutaneous transhepatic cholangiogram (PTC) is performed by a radiologist using fluoroscopic guidance.[7] The liver is punctured to enter the peripheral intrahepatic bile duct system. An iodine-based contrast medium is injected into the biliary system and flows through the ducts. Obstruction can be identified on the fluoroscopic monitor.
    • It is especially useful for lesions proximal to the common hepatic duct.
    • The technique is not easy and requires considerable experience. More than 25% of attempts fail (most often when the ducts cannot be well visualized because they are not dilated, ie, not obstructed.)
    • Complications of this procedure include the possibility of allergic reaction to the contrast medium, peritonitis with possible intraperitoneal hemorrhage, sepsis, cholangitis, subphrenic abscess, and lung collapse. Severe complications occur in approximately 3% of cases.
    • The accuracy of PTC in elucidating the cause and site of obstructive jaundice is 90-100% for causes within the biliary tract. The biliary tree can be successfully visualized in 99% of patients with dilated bile ducts and in 40-90% if the bile ducts are not dilated. Still, ERCP is generally preferred, and PTC is reserved for use if ERCP fails or when altered anatomy precludes accessing the ampulla.
  • Endoscopic ultrasound (EUS) combines endoscopy and US to provide remarkably detailed images of the pancreas and biliary tree. It uses higher-frequency ultrasonic waves compared to traditional US (3.5 MHz vs 20 MHz) and allows diagnostic tissue sampling via EUS-guided fine-needle aspiration (EUS-FNA).[8]
    • Although endoscopic retrograde cholangiography is the procedure of choice for biliary decompression in obstructive jaundice, biliary access is not always achievable, in which case, interventional endoscopic ultrasound-guided cholangiography (IEUC) may offer an alternative to percutaneous transhepatic cholangiography (PTC). Maranki et al reported their 5-year experience with IEUC in patients who had unsuccessful treatment with ERCP.[9] The investigators used either a transgastric-transhepatic or transenteric-transcholedochal approach to the targeted biliary duct, then advanced a stent over the wire into the biliary tree.[9]
    • Of the 49 patients who underwent IEUC, the cause of biliary obstruction was a malignancy in 35, whereas 14 had a benign etiology.[9] Forty-one of the 49 patients (84%) had successful overall therapy with IEUC, with an overall complication rate of 16%. Resolution of obstruction had an 83% success rate (n = 29). The transenteric-transcholedochal approach was used in 14 patients, with successful biliary decompress in 86% (n = 12).[9] No procedure-related deaths were reported. Thus, overall, the intrahepatic approach was successful in 73% (29/40) of cases, and the extrahepatic approach was successful in 78% (7/9) cases.[9]
    • An international multicenter retrospective analysis found comparable short-term outcomes between EUS-guided biliary drainage and ERCP in 208 patients with&malignant distal common bile duct obstruction who required the placement of self-expandable stents.[10] Ninety-seven of 104 patients (94.23%) who underwent EUS-guided biliary drainage and 98 of 104 patients (93.26%) who underwent ERCP had successful stent placement (P = 1.00); each group had an 8.65% frequency of adverse events, and the mean procedural times were similar (35.95 mins vs 30.10 mins, respectively; P = 0.05). However, the rates of postprocedure pancreatitis were higher in the ERCP group (4.8% vs 0%, P = 0.059).[10]
    • EUS has been reported to have up to a 98% diagnostic accuracy in patients with obstructive jaundice. This makes ERCP unnecessary in patients who are found to not have extrahepatic obstruction. In addition, those patients who may require operative biliary drainage are reliably identified and similarly need not undergo ERCP for further evaluation.[11]
    • EUS provides highly detailed imaging of the pancreas. The sensitivity of EUS for the identification of focal mass lesions has been reported to be superior to that of CT scanning, both traditional and spiral, particularly for tumors smaller than 3 cm in diameter.
    • Compared to MRCP for the diagnosis of biliary stricture, EUS has been reported to be more specific (100% vs 76%) and to have a much greater positive predictive value (100% vs 25%), although the two have equal sensitivity (67%).
    • Neither transabdominal US nor CT scanning can help reliably exclude the presence of choledocholithiasis. ERCP is highly accurate for this diagnosis but, because of the associated risk of pancreatitis, is generally reserved for patients with known common duct stones. EUS has been reported to have sensitivity approximately equal to both ERCP and MRCP for the detection of common duct stones, with minimal risks directly associated with the procedure.
    • EUS is more portable than ERCP or MRCP and is useful for patients in the intensive care unit. EUS (if performed in the fluoroscopy suite) can be followed immediately by therapeutic ERCP, which saves time.
    • The positive yield of EUS-FNA for cytology in patients with malignant obstruction has been reported to be as high as 96%.
Previous
 
 
Contributor Information and Disclosures
Author

Jennifer Lynn Bonheur, MD Attending Physician, Division of Gastroenterology, Lenox Hill Hospital

Jennifer Lynn Bonheur, MD is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, New York Society for Gastrointestinal Endoscopy, New York Academy of Sciences, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Peter F Ells, MD Associate Professor, Division of Gastroenterology-Hepatology, Albany Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS Professor of Medicine, Director of Digestive Diseases, Medical Director of Nutrition Support, Medical Director of Gastrointestinal Endoscopy, Internal Medicine Department, University of Mississippi Medical Center; Clinical Professor, University of Mississippi School of Pharmacy

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS is a member of the following medical societies: American Academy of Clinical Toxicology, American Society for Gastrointestinal Endoscopy, American Federation for Clinical Research, American Association for the Study of Liver Diseases, American College of Forensic Examiners Institute, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous coauthor Flavio R Kamenetz, MD, PhD, to the development and writing of this article.

References
  1. Center SA. Diseases of the gallbladder and biliary tree. Vet Clin North Am Small Anim Pract. 2009 May. 39(3):543-98. [Medline].

  2. Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009 Apr 16. epub ahead of print. [Medline].

  3. Bektas M, Dokmeci A, Cinar K, et al. Endoscopic management of biliary parasitic diseases. Dig Dis Sci. 2009 Jun 10. epub ahead of print. [Medline].

  4. Chu YC, Yang CC, Yeh YH, Chen CH, Yueh SK. Double-balloon enteroscopy application in biliary tract disease-its therapeutic and diagnostic functions. Gastrointest Endosc. 2008 Jun 16. [Medline].

  5. Aabakken L, Bretthauer M, Line PD. Double-balloon enteroscopy for endoscopic retrograde cholangiography in patients with a Roux-en-Y anastomosis. Endoscopy. 2007 Dec. 39(12):1068-71. [Medline].

  6. Nanashima A, Abo T, Sakamoto I, et al. Three-dimensional cholangiography applying C-arm computed tomography in bile duct carcinoma: a new radiological technique. Hepatogastroenterology. 2009 May-Jun. 56(91-92):615-8. [Medline].

  7. Niu H, Gao W, Cheng J, Liu B, Li Y, Huang K, et al. Improvement of Percutaneous Transhepatic Biliary Internal-External Drainage and its Initial Experience in Patients with Malignant Obstruction of the Upper Biliary Tree. Hepatogastroenterology. 2011 Nov 24. 59(117):[Medline].

  8. Hanada K, Iiboshi T, Ishii Y. Endoscopic ultrasound-guided choledochoduodenostomy for palliative biliary drainage in cases with inoperable pancreas head carcinoma. Dig Endosc. 2009 Jul. 21 suppl 1:S75-8. [Medline].

  9. Maranki J, Hernandez AJ, Arslan B, et al. Interventional endoscopic ultrasound-guided cholangiography: long-term experience of an emerging alternative to percutaneous transhepatic cholangiography. Endoscopy. 2009 Jun. 41(6):532-8. [Medline].

  10. Dhir V, Itoi T, Khashab MA, et al. Multicenter comparative evaluation of endoscopic placement of expandable metal stents for malignant distal common bile duct obstruction by ERCP or EUS-guided approach. Gastrointest Endosc. 2014 Dec 4. [Medline].

  11. Mutignani M, Iacopini F, Perri V, et al. Endoscopic gallbladder drainage for acute cholecystitis: technical and clinical results. Endoscopy. 2009 Jun. 41(6):539-46. [Medline].

  12. Jaganmohan S, Lee JH. Self-expandable metal stents in malignant biliary obstruction. Expert Rev Gastroenterol Hepatol. 2012 Jan. 6(1):105-14. [Medline].

  13. Gwon DI, Ko GY, Sung KB, Yoon HK, Shin JH, Kim JH, et al. A novel double stent system for palliative treatment of malignant extrahepatic biliary obstructions: a pilot study. AJR Am J Roentgenol. 2011 Nov. 197(5):W942-7. [Medline].

  14. Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol. 2009 Aug 4. [Medline].

  15. Adamek HE, Albert J, Weitz M. A prospective evaluation of magnetic resonance cholangiopancreatography in patients with suspected bile duct obstruction. Gut. 1998 Nov. 43(5):680-3. [Medline].

  16. Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician. 2000 Mar 15. 61(6):1673-80, 1687-8. [Medline].

  17. American Society of Gastrointestinal Endoscopy. Technology status evaluation: magnetic resonance pancreatography. American Society of Gastrointestinal Endoscopy Clinical Guidelines. Oak Brook, Ill: ASGE; 1998.

  18. Bass NM. Sclerosing cholangitis and recurrent pyogenic cholangitis. Feldman M, ed. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: WB Saunders; 1998. 1006-18.

  19. Beers MH, Berkow R. Hepatic and biliary disorders. Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co; 1999. chap 46.

  20. Bilhartz MH, Horton JD. Gallstone disease and its complications. Feldman M, ed. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: WB Saunders; 1998. 948-72.

  21. Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol. 1998 Sep. 93(9):1510-7. [Medline].

  22. Cotran RS, Kumar V, Robbins SL. The biliary system. Schoen FJ, ed. Robbins Pathologic Basis of Disease. 5th ed. Philadelphia: WB Saunders; 1994. 883-96.

  23. Erickson RA, Garza AA. EUS with EUS-guided fine-needle aspiration as the first endoscopic test for the evaluation of obstructive jaundice. Gastrointest Endosc. 2001 Apr. 53(4):475-84. [Medline].

  24. Friedman LS. The liver, biliary tract, and pancreas. Tiernery LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 39th ed. New York: McGraw-Hill; 2000. 656-97.

  25. Fukuda Y, Tsuyuguchi T, Sakai Y. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc. 2005 Sep. 62(3):374-82.

  26. Hanau LH, Steigbigel NH. Acute (ascending) cholangitis. Infect Dis Clin North Am. 2000 Sep. 14(3):521-46. [Medline].

  27. Kaplan LM, Isselbacher KJ. Jaundice. Fauci AS, Longo DL, Kasper DL, Martin JB, Hauser SL, Braunwald E, Isselbacher KJ, Wilson JD, eds. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill; 1998. 249-55.

  28. Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. Brenner BM, ed. Brenner and Rector's The Kidney. 6th ed. WB Saunders; 2000. 1143.

  29. Kok KY, Yapp SK. Tuberculosis of the bile duct: a rare cause of obstructive jaundice. J Clin Gastroenterol. 1999 Sep. 29(2):161-4. [Medline].

  30. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000 Sep. 84(5):1275-311, x. [Medline].

  31. Lindnor KD. Primary biliary cirrhosis. Feldman M, ed. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: WB Saunders; 1998. 1279.

  32. Lopera JE, Soto JA, Munera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology. 2001 Jul. 220(1):90-6. [Medline].

  33. Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 1999 Aug. 3(3):509-28, viii. [Medline].

  34. Mallery S, Van Dam J. Advances in diagnostic and therapeutic endoscopy. Med Clin North Am. 2000 Sep. 84(5):1059-83. [Medline].

  35. Maze M, Bass N. Anesthesia and the hepatobiliary system. Miller R, ed. Anesthesia. 5th ed. New York: Churchill Livingstone; 2000. 1968-9.

  36. Nissen D. Rifampin (002188). In: Mosby's Drug Consult 2002. 1st ed. Orlando, Fla: Harcourt Health Sciences; 2002.

  37. Ostroff JW, LaBerge JM. Endoscopic and radiologic treatment of biliary disease. Feldman M, ed. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: WB Saunders; 1998. 1043.

  38. Paumgartner G. Nonsurgical management of gallstone disease. Feldman M, ed. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: WB Saunders; 1998. 984-92.

  39. Ravel R. Liver and biliary tract tests. Ravel R, ed. Clinical Laboratory Medicine. 6th ed. St. Louis, Mo: Mosby-Year Book; 1995. 309-29.

  40. Rossi RL, Traverso LW, Pimentel F. Malignant obstructive jaundice. Evaluation and management. Surg Clin North Am. 1996 Feb. 76(1):63-70. [Medline].

  41. Scheiman JM, Carlos RC, Barnett JL, et al. Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis. Am J Gastroenterol. 2001 Oct. 96(10):2900-4. [Medline].

  42. Shaker R, Dua KS, Koch TR. Gastroenterologic disorders. Duthie EH, ed. Practice of Geriatrics. 3rd ed. Philadelphia: WB Saunders; 1998. 514-5.

  43. Shim CS, Cheon YK, Cha SW. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy. 2005 May. 37(5):425-33.

  44. Vlahcevic ZR, Heuman DM. Diseases of the gallbladder and bile ducts. Goldman G, ed. Cecil Textbook of Medicine. 21 ed. Philadelphia: WB Saunders; 2000. 821-33.

  45. Yeh TS, Chen NH, Jan YY, et al. Obstructive jaundice caused by biliary tuberculosis: spectrum of the diagnosis and management. Gastrointest Endosc. 1999 Jul. 50(1):105-8. [Medline].

  46. Yeh TS, Jan YY, Tseng JH. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol. 2000 Feb. 95(2):432-40.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.